The following information is for healthcare professionals licensed in the United States. Countries outside the United States have different practice, legal and regulatory requirements which may require different information. Information may not be appropriate for use outside of the United States.
Close Menu
Open Menu

Comparison of Dotarem® to Gadavist® for Overall Visualization and
Characterization in the MRI Diagnosis of Primary Brain Tumors

Despite the difference in relaxivity between these 2 GBCAs

There Is No Measurable Difference in Clinical Benefit Observed Between Dotarem® and Gadavist®1

as demonstrated by the REMIND Study, a multicenter, double-blind, randomized, controlled intraindividual crossover study.1


For all readers, more than 90% presented with good or excellent overall lesion visualization and characterization with either of the two contrast agents.1

Rate of patients with overall lesion visualization and characterization scored good/excellent or poor/fair

Additionally, in most cases there was no preference of the readers for either contrast agent regarding border delineation, internal morphology, and the qualitative degree of contrast enhancement despite quantitative mean lesion percentage enhancement being higher with gadobutrol.1

Border Delineation

Border Delineation

Internal Morphology

Degree of Contrast Enhancement

Case Studies

The REMIND Study demonstrates non-inferiority in lesion visualization and characterization for both Dotarem and Gadavist.1

A 46-year-old woman with glioblastoma

After injection of Dotarem

After injection of Gadavist

A 74-year-old man with a high-grade glioma

After injection of Dotarem

After injection of Gadavist


This study “demonstrates the non-inferiority of gadoterate meglumine [Dotarem] versus gadobutrol [Gadavist] for overall visualization and characterization of primary brain tumors.”1

  • For all readers in the REMIND Study, more than 90% of patient images were scored with good or excellent overall lesion visualization and characterization with either Dotarem® or Gadavist®.1
  • The REMIND Study also confirmed low incidence of immediate reported AEs with Dotarem® and with Gadavist®, as shown in multiple previous studies.1,3,4
  • Dotarem® is the first imaging contrast with macrocyclic and ionic structure for high thermodynamic and kinetic stability.5,6
  • Dotarem® is not only trusted for high molecular stability5,6; the REMIND Study demonstrates that it is as effective as Gadavist® for MRI diagnosis of primary brain tumors.1

Stability Down to its
Molecular Core

Guerbet's research team designed Dotarem® (gadoterate meglumine) with a unique profile, providing the highest molecular stability to minimize the risk of gadolinium release.5,6

Explore Dotarem at www.Guerbet-us.com

Want more information?

Personal Information

First Name*


Last Name*


Address Line 1*

Address Line 2



Postal Code*




Place of Employment*

Stay Connected With Guerbet Updates

There was a problem with your submission. Please complete the form and try again.

Thank you, we'll be in touch.




Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.

  • The risk for NSF appears highest among patients with:
    • Chronic, severe kidney disease (GFR < 30 mL/min/1.73m2), or
    • Acute kidney injury.
  • Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension, diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
  • For patients at highest risk for NSF, do not exceed the recommended DOTAREM dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration.

Indications and Usage

DOTAREM® (gadoterate meglumine) injection is a prescription gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.


History of clinically important hypersensitivity reactions to DOTAREM.

Warnings and Precautions

Adverse Reactions

Use in Specific Populations

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see the full Prescribing Information, including the patient Medication Guide, for additional important safety information.

Reimbursement Information*

For U.S. Reimbursement Information, please see attached information for Hospital Outpatient settings and Freestanding/Independent Diagnostic Testing Facility (IDTF) settings.

For further assistance, please contact DOTAREM Reimbursement Support at 1-855-368-2736, Monday–Friday, 7 am–7 pm ET.

1. Maravilla K et al. Comparison of Gadoterate Meglumine and Gadobutrol in the Diagnosis of Primary Brain Tumors: A Double-Blind Randomized Controlled Intraindividual Crossover Study (the REMIND Study). 2017 June 29. doi: 10:3174/ajnr.A5316. [Epub ahead of print]. 2. Dotarem [package insert]. Princeton, NJ: Guerbet LLC; Oct 2019. 3. de Kerviler E et al. Adverse reactions to gadoterate meglumine: review of ov¬oer 25 years of clinical use and more than 50 million doses. Invest Radiol 2016;51:544–51 CrossRef Medline. 4. Endrikat J et al. Safety of gadobutrol: results from 42 clinical phase II to IV studies and postmarketing surveillance after 29 million applications. Invest Radiol 2016;51: 537–43 CrossRef Medline. 5. Port M et al. Efficiency,thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals. 2008;21:469-90. 6. Frenzel T et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37°C. Invest Radiol. 2008;43:817-828.

DOTAREM® is a registered trademark of Guerbet LLC, and is available by prescription only.

Gadavist® is a registered trademark of the Bayer group of companies, and is available by prescription only.

Learn more at guerbet-us.com.
Legal © 2021 Guerbet Group